High BMI Impacts Survival in Pancreatic Cancer

This article originally appeared here.
Share this content:
High BMI Linked to Worse Survival in Pancreatic Cancer
High BMI Linked to Worse Survival in Pancreatic Cancer

(HealthDay News) -- For patients with pancreatic cancer, higher prediagnostic body mass index (BMI) is associated with decreased survival, according to a study published online Oct. 21 in the Journal of Clinical Oncology.

Chen Yuan, from Brigham and Women's Hospital in Boston, and colleagues used data from 902 patients from two large prospective cohorts to examine pancreatic cancer survival by prediagnostic BMI.

The researchers found that the risk of death was significantly increased for patients with BMI ≥35 kg/m² versus those with BMI of less than 25 kg/m² (hazard ratio, 1.53), which was unchanged after adjustment for stage. With longer lag times between reported BMI and cancer diagnosis, the correlation of BMI with survival was stronger.

Among patients with BMI collected 18 to 20 years before diagnosis, hazard ratio for death was 2.31 comparing obese with healthy-weight patients. The correlation was stronger among never-smokers (hazard ratio, 1.61; P trend = 0.002) than among never-smokers (hazard ratio, 1.36; P trend = 0.63). There was a correlation between higher prediagnostic BMI with more advanced stage at diagnosis -- 72.5$ and 59.4%, respectively, of obese and healthy-weigh patients presented with metastatic disease.

"These data emphasize the link between chronic alterations in systemic metabolism and pancreatic cancer survival and suggest obesity-related metabolic pathways for possible therapeutic intervention in patients with pancreatic adenocarcinoma," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs